This study looked at the effect of canagliflozin (Invokana) on hospitalization occurrence in patients with type 2 diabetes (T2D). It found that patients treated with canagliflozin were less likely to be admitted to the hospital than patients treated with placebo. 

This study examined the association between blood glucose levels, blood pressure, mortality risk and risk of diabetic complications. The authors concluded that high blood pressure and an HbA1c greater than 7% are associated with the risk of mortality and with the risk of diabetic complications in patients with diabetes.

The authors evaluated the effectiveness and safety of canagliflozin for type 2 diabetes that could not be controlled with metformin therapy.

This study looked at the impact of carotenoids to protect against the development of diabetic retinopathy (DR; eye disease). It found that daily carotenoid supplementation may improve the health of the retina and improve subtle changes in vision caused by DR.

This study evaluated the efficacy and safety of canakinumab on improving glucose control in metformin treated patients with type 2 diabetes.

This review looked at whether a vegan diet can improve type 2 diabetes (T2D). It found that a vegan diet can lower glucose (sugar) levels for people with T2D.

This study compared the effect of administering 1.5 mg, 3 mg, and 4.5 mg of dulaglutide (Trulicity) on overall bodyweight reduction in patients with type 2 diabetes (T2D). The authors concluded that higher doses of dulaglutide caused more weight loss in these patients.

This study looked at the risk of urogenital infections in patients with diabetes taking sodium-glucose co-transporter 2 (SGLT2) inhibitors. It found that SGLT2 inhibitors increase the risk of urogenital infections in women over 50 years of age, especially in the first month of treatment.

This review looked at whether bariatric (weight-loss) surgery (BS) improves life expectancy for adults with or without type 2 diabetes (T2D). It found that BS improved life expectancy for people with diabetes by 9.3 years.

This study compared mecobalamin (vitamin B12) injections with mecobalamin tablets for the treatment of diabetic peripheral neuropathy (DPN; nerve damage). It showed that after 8 weeks of treatment, patients treated with mecobalamin injections showed signs of nerves being repaired, while no effects were seen in those taking the tablets.